A detailed history of Sei Investments CO transactions in Legend Biotech Corp stock. As of the latest transaction made, Sei Investments CO holds 46,492 shares of LEGN stock, worth $2.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,492
Previous 45,790 1.53%
Holding current value
$2.29 Million
Previous $2.57 Million 19.82%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$39.5 - $57.22 $27,729 - $40,168
702 Added 1.53%
46,492 $2.06 Million
Q1 2024

May 07, 2024

SELL
$55.06 - $69.99 $99,988 - $127,101
-1,816 Reduced 3.81%
45,790 $2.57 Million
Q4 2023

Feb 14, 2024

SELL
$57.25 - $69.74 $1.52 Million - $1.86 Million
-26,637 Reduced 35.88%
47,606 $2.86 Million
Q3 2023

Nov 14, 2023

BUY
$63.16 - $76.5 $381,044 - $461,524
6,033 Added 8.84%
74,243 $4.99 Million
Q2 2023

Aug 11, 2023

BUY
$46.28 - $75.01 $980,580 - $1.59 Million
21,188 Added 45.06%
68,210 $4.71 Million
Q1 2023

May 12, 2023

SELL
$43.42 - $57.37 $313,970 - $414,842
-7,231 Reduced 13.33%
47,022 $2.27 Million
Q4 2022

Feb 10, 2023

BUY
$38.8 - $55.46 $88,774 - $126,892
2,288 Added 4.4%
54,253 $2.71 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $729,237 - $1.09 Million
19,115 Added 58.19%
51,965 $2.12 Million
Q2 2022

Aug 15, 2022

SELL
$33.54 - $55.0 $96,762 - $158,675
-2,885 Reduced 8.07%
32,850 $1.81 Million
Q1 2022

May 13, 2022

BUY
$31.02 - $48.18 $363,244 - $564,187
11,710 Added 48.74%
35,735 $1.3 Million
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $406,134 - $562,506
9,872 Added 69.75%
24,025 $1.12 Million
Q3 2021

Nov 12, 2021

BUY
$35.31 - $50.56 $20,515 - $29,375
581 Added 4.28%
14,153 $716,000
Q2 2021

Aug 06, 2021

BUY
$25.8 - $41.09 $350,157 - $557,673
13,572 New
13,572 $557,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $8.25B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.